Primovist Regulatory Post Marketing Surveillance (PMS)

Bayer

Status: Completed

Conditions: Liver

Treatments: Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)

Study type: Observational

Funder types: Industry

Identifiers

NCT00924248

14332

PR0810KR (Other Identifier)

Details and patient eligibility

About

The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice

Enrollment: 4,358 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient who take Primovist for liver MRI

Exclusion criteria

• Patients who belong to the contraindication on the product label

Trial design

4,358 participants in 1 patient group

Group 1

Treatment:

Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)